These findings implicate TRIM31 in TMZ resistance via activation of the PI3K/AKT/p53 axis, providing a mechanistic basis for therapeutic resistance and a candidate target for glioma treatment enhancement. Here, TRIM31 is linked to central nervous system cancer.